vs
Atara Biotherapeutics, Inc.（ATRA）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
Atara Biotherapeutics, Inc.的季度营收约是Arcadia Biosciences, Inc.的1.8倍（$1.6M vs $901.0K），Arcadia Biosciences, Inc.同比增速更快（-25.8% vs -95.1%），过去两年Arcadia Biosciences, Inc.的营收复合增速更高（-4.5% vs -75.9%）
Atara Biotherapeutics是一家临床阶段生物技术企业，专注研发同种异体T细胞免疫疗法，适应症覆盖肿瘤、自身免疫疾病及感染性疾病，业务主要布局北美、欧洲及亚太市场，致力于为有未满足医疗需求的患者提供新型治疗方案。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
ATRA vs RKDA — 直观对比
营收规模更大
ATRA
是对方的1.8倍
$901.0K
营收增速更快
RKDA
高出69.3%
-95.1%
两年增速更快
RKDA
近两年复合增速
-75.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6M | $901.0K |
| 净利润 | — | $-1.3M |
| 毛利率 | — | 21.4% |
| 营业利润率 | — | -152.8% |
| 净利率 | — | -148.3% |
| 营收同比 | -95.1% | -25.8% |
| 净利润同比 | 73.2% | 67.1% |
| 每股收益（稀释后） | — | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRARKDA
| Q4 25 | $1.6M | $901.0K | ||
| Q3 25 | $3.5M | $1.3M | ||
| Q2 25 | $17.6M | $1.5M | ||
| Q1 25 | $98.1M | $1.2M | ||
| Q4 24 | $32.8M | $1.2M | ||
| Q3 24 | $40.2M | $1.5M | ||
| Q2 24 | $28.6M | $1.3M | ||
| Q1 24 | $27.4M | $987.0K |
净利润ATRARKDA
| Q4 25 | — | $-1.3M | ||
| Q3 25 | $-4.3M | $856.0K | ||
| Q2 25 | $2.4M | $-4.5M | ||
| Q1 25 | $38.0M | $2.6M | ||
| Q4 24 | $-12.7M | $-4.1M | ||
| Q3 24 | $-21.9M | $-1.6M | ||
| Q2 24 | $-19.0M | $1.1M | ||
| Q1 24 | $-31.8M | $-2.4M |
毛利率ATRARKDA
| Q4 25 | — | 21.4% | ||
| Q3 25 | — | 32.1% | ||
| Q2 25 | — | 43.4% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | — | 31.9% | ||
| Q3 24 | — | 32.9% | ||
| Q2 24 | — | 51.5% | ||
| Q1 24 | — | 52.3% |
营业利润率ATRARKDA
| Q4 25 | — | -152.8% | ||
| Q3 25 | -103.5% | -88.5% | ||
| Q2 25 | 18.2% | -34.4% | ||
| Q1 25 | 39.5% | 44.2% | ||
| Q4 24 | -37.3% | -187.7% | ||
| Q3 24 | -54.1% | -114.5% | ||
| Q2 24 | -63.7% | — | ||
| Q1 24 | -114.2% | -160.9% |
净利率ATRARKDA
| Q4 25 | — | -148.3% | ||
| Q3 25 | -124.6% | 65.7% | ||
| Q2 25 | 13.6% | -306.4% | ||
| Q1 25 | 38.7% | 216.6% | ||
| Q4 24 | -38.8% | -334.5% | ||
| Q3 24 | -54.5% | -104.9% | ||
| Q2 24 | -66.5% | 81.2% | ||
| Q1 24 | -116.1% | -245.5% |
每股收益（稀释后）ATRARKDA
| Q4 25 | — | $-0.97 | ||
| Q3 25 | $-0.32 | $0.62 | ||
| Q2 25 | $0.19 | $-3.26 | ||
| Q1 25 | $3.50 | $1.90 | ||
| Q4 24 | $0.27 | $-2.99 | ||
| Q3 24 | $-2.93 | $-1.18 | ||
| Q2 24 | $-3.10 | $0.78 | ||
| Q1 24 | $-5.65 | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.5M | $4.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-38.5M | $4.1M |
| 总资产 | $20.2M | $6.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ATRARKDA
| Q4 25 | $8.5M | $4.6M | ||
| Q3 25 | $13.7M | $5.9M | ||
| Q2 25 | $22.3M | $4.4M | ||
| Q1 25 | $13.8M | $3.2M | ||
| Q4 24 | $42.5M | $4.2M | ||
| Q3 24 | $67.2M | $6.6M | ||
| Q2 24 | $35.3M | $8.1M | ||
| Q1 24 | $46.2M | $8.5M |
股东权益ATRARKDA
| Q4 25 | $-38.5M | $4.1M | ||
| Q3 25 | $-36.6M | $5.4M | ||
| Q2 25 | $-35.0M | $4.5M | ||
| Q1 25 | $-55.1M | $8.9M | ||
| Q4 24 | $-97.3M | $6.2M | ||
| Q3 24 | $-90.5M | $10.3M | ||
| Q2 24 | $-110.9M | $11.7M | ||
| Q1 24 | $-98.3M | $10.6M |
总资产ATRARKDA
| Q4 25 | $20.2M | $6.5M | ||
| Q3 25 | $30.2M | $8.6M | ||
| Q2 25 | $36.9M | $7.8M | ||
| Q1 25 | $62.0M | $13.0M | ||
| Q4 24 | $109.1M | $13.5M | ||
| Q3 24 | $142.7M | $15.2M | ||
| Q2 24 | $117.3M | $17.4M | ||
| Q1 24 | $165.3M | $16.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-50.9M | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ATRARKDA
| Q4 25 | $-50.9M | $-861.0K | ||
| Q3 25 | $-9.8M | $-257.0K | ||
| Q2 25 | $-7.3M | $-2.0M | ||
| Q1 25 | $-28.1M | $-1.6M | ||
| Q4 24 | $-24.5M | $-2.2M | ||
| Q3 24 | $-4.0M | $-1.8M | ||
| Q2 24 | $-10.6M | $-2.5M | ||
| Q1 24 | $-29.6M | $-3.2M |
自由现金流ATRARKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-24.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-10.7M | $-2.5M | ||
| Q1 24 | $-29.7M | $-3.2M |
自由现金流率ATRARKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -75.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -37.3% | -188.3% | ||
| Q1 24 | -108.7% | -326.5% |
资本支出强度ATRARKDA
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.3% | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.1% | 0.2% | ||
| Q1 24 | 0.5% | 1.3% |
现金转化率ATRARKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | -3.07× | — | ||
| Q1 25 | -0.74× | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
